You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,056,133


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,056,133
Title:Pharmaceutical kit and method for treating cancer
Abstract: This invention is related to the field of cancer treatment, more specifically to gene therapy in combination with a suitable chemotherapeutic agent. The present invention is related to a new oncolytic virus, which is able to inhibit the growth of malignant tumors or is a treatment of hyperproliferative mammalian cells, or is a treatment of cancer. The oncolytic virus works in combination with a suitable chemotherapeutic agent. More specifically, the present invention provides a pharmaceutical kit comprising an oncolytic adenovirus and a chemotherapeutic agent, and a method for the treatment of cancer.
Inventor(s): Podhajcer; Osvaldo (Buenos Aires, AR), Gidekel; Manuel (Santiago, CL), Cafferata; Eduardo (Buenos Aires, AR), Weber; Helga (Pucon, CL)
Assignee: CTI-S.A. (Santiago, CL)
Application Number:13/506,865
Patent Claims:1. A pharmaceutical kit, comprising: a. an oncolytic adenovirus, comprising 3 regions: i. binding region; ii. promoter region; iii. insulator region; b. a chemotherapeutic agent; said oncolytic adenovirus DNA sequence is anyone of SEQ ID NOs 4 and 5, or a sequence with at least 80% homology to anyone of SEQ ID NOs: 4 and 5.

2. The pharmaceutical kit according to claim 1, wherein the adenovirus is a serotype 5 adenovirus.

3. The pharmaceutical kit according to claim 2, wherein the binding domain of the serotype 5 adenovirus has been replaced with the binding domain from a serotype 3 adenovirus.

4. The pharmaceutical kit according to claim 1, wherein the promoter region is the promoter of the human Cdc25B gene, or a sequence with at least 80% homology to SEQ ID NO: 1.

5. The pharmaceutical kit according to claim 4, wherein the promoter is a fragment of the human Cdc25B gene.

6. The pharmaceutical kit, according to claim 5, wherein the promoter sequence is SEQ ID NO: 1, or SEQ ID NO: 2 or a sequence with at least 80% homology to SEQ ID NO: 1, or at least 80% homology to SEQ ID NO: 2.

7. The pharmaceutical kit according to claim 1, wherein the insulator sequence is SEQ ID NO: 3 or a sequence with at least 80% homology to SEQ ID NO: 3.

8. The pharmaceutical kit according to claim 1, wherein the chemotherapeutic agent is selected from: ARA-C, aclarubicin, actinomycin, alemtuzumab, alitretinoin, altretamine, aminolevulinicacid, amsacrine, anagrelide, antiestrogen, antineoplastic, arsenictrioxide, asparaginase, azacitidine, 8-azaguanine, bevacizumab, bexarotene, bleomycin, bortezomib, bropirimine, busulfan, cabazitaxel, capecitabine, carboplatin, carboquone, carmofur, carmustine, catumaxomab, celecoxib, cetuximab, chemicallylinkedfab, chlorambucil, cisplatin, cladribine, clofarabine, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, daunorubicin, decitabine, demecolcine, denileukindiftitox, dha-paclitaxel, dichloroaceticacid, docetaxel, doxorubicin, edrecolomab, efaproxiral, epirubicin, epoxomicin, erlotinib, estramustine, etoglucid, etoposide, everolimus, ferruginol, fludarabine, fluorouracil, fotemustine, fulvestrant, gefitinib, gemcitabine, gemtuzumabozogamicin, glembatumumabvedotin, hydroxycarbamide, idarubicin, ifosfamide, imatinib, irinotecan, ixabepilone, lapatinib, lipoplatin, lomustine, lonidamine, mafosfamide, mannosulfan, masoprocol, mechlorethamine, melphalan, mercaptopurine, methotrexate, methylaminolevulinate, metoart, miltefosine, mitobronitol, mitoguazone, mitomycin, mitotane, mitoxantrone, monomethylauristatine, mubritinib, myocet, nafoxidine, nelarabine, nilotinib, nimustine, oblimersen, omacetaxinemepesuccinate, ortataxel, oxaliplatin, paclitaxel, panitumumab, pazopanib, pegaspargase, pelretin, pemetrexed, pentostatin, personalizedmedicine, picoplatin, pipobroman, pirarubicin, pixantrone, plicamycin, porfimersodium, prednimustine, procarbazine, psc833, raltitrexed, reditux, rituximab, romidepsin, satraplatin, semustine, sorafenib, sparsomycin, streptozotocin, sunitinib, talampanel, tamibarotene, taxane, taxoid, tegafur, temoporfin, temozolomide, temsirolimus, teniposide, tesetaxel, thiotepa, thymidylatesynthaseinhibitor, tiazofurin, tioguanine, toceranib, topotecan, trabectedin, trastuzumab, trastuzumabemtansine, treosulfan, tretinoin, triaziquone, trofosfamide, valrubicin, vascular-targetingagent, vinblastine, vincristine, vindesine, vinorelbine, vorinostat, zorubicin.

9. The pharmaceutical kit according to claim 1, wherein the chemotherapeutic agent is gemcitabine.

10. A method of treating cancer in a patient in need of such treatment, said treatment comprising administering the oncolytic adenovirus and a chemotherapeutic agent from the pharmaceutical kit described in claim 1.

11. The method of claim 10, wherein the cancer is selected from ovarian cancer, pancreatic cancer, gastric cancer, a non-small cell lung cancer, small cell lung cancer, primary peritoneal cancer, hepatocarcinoma, melanoma, retinoblastoma, breast tumor, colorectal carcinoma, leukemia, lymphoma, brain tumor, cervical carcinoma, sarcoma, prostate tumor, bladder tumor, tumor of the reticuloendothelial tissues, Wilm's tumor, astrocytoma, glioblastoma, neuroblastoma, ovarian carcinoma, osteosarcoma, renal cancer, or head and neck cancer.

12. The method of claim 10, wherein the cancer is characterized by an over expression of Cdc25B.

13. The method of claim 10, wherein the patient receives 1 to 10.sup.10 viral particles per tumor.

14. The method of claim 10, wherein the chemotherapeutic agent is administered 72 hours after administration of the oncolytic adenovirus.

15. The method of claim 10, wherein the chemotherapeutic agent is selected from: ARA-C, aclarubicin, actinomycin, alemtuzumab, alitretinoin, altretamine, aminolevulinicacid, amsacrine, anagrelide, antiestrogen, antineoplastic, arsenictrioxide, asparaginase, azacitidine, 8-azaguanine, bevacizumab, bexarotene, bleomycin, bortezomib, bropirimine, busulfan, cabazitaxel, capecitabine, carboplatin, carboquone, carmofur, carmustine, catumaxomab, celecoxib, cetuximab, chemicallylinkedfab, chlorambucil, cisplatin, cladribine, clofarabine, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, daunorubicin, decitabine, demecolcine, denileukindiftitox, dha-paclitaxel, dichloroaceticacid, docetaxel, doxorubicin, edrecolomab, efaproxiral, epirubicin, epoxomicin, erlotinib, estramustine, etoglucid, etoposide, everolimus, ferruginol, fludarabine, fluorouracil, fotemustine, fulvestrant, gefitinib, gemcitabine, gemtuzumabozogamicin, glembatumumabvedotin, hydroxycarbamide, idarubicin, ifosfamide, imatinib, irinotecan, ixabepilone, lapatinib, lipoplatin, lomustine, lonidamine, mafosfamide, mannosulfan, masoprocol, mechlorethamine, melphalan, mercaptopurine, methotrexate, methylaminolevulinate, metoart, miltefosine, mitobronitol, mitoguazone, mitomycin, mitotane, mitoxantrone, monomethylauristatine, mubritinib, myocet, nafoxidine, nelarabine, nilotinib, nimustine, oblimersen, omacetaxinemepesuccinate, ortataxel, oxaliplatin, paclitaxel, panitumumab, pazopanib, pegaspargase, pelretin, pemetrexed, pentostatin, personalizedmedicine, picoplatin, pipobroman, pirarubicin, pixantrone, plicamycin, porfimersodium, prednimustine, procarbazine, psc833, raltitrexed, reditux, rituximab, romidepsin, satraplatin, semustine, sorafenib, sparsomycin, streptozotocin, sunitinib, talampanel, tamibarotene, taxane, taxoid, tegafur, temoporfin, temozolomide, temsirolimus, teniposide, tesetaxel, thiotepa, thymidylatesynthaseinhibitor, tiazofurin, tioguanine, toceranib, topotecan, trabectedin, trastuzumab, trastuzumabemtansine, treosulfan, tretinoin, triaziquone, trofosfamide, vairubicin, vascular-targetingagent, vinblastine, vincristine, vindesine, vinorelbine, vorinostat, zorubicin.

16. The method of claim 10, wherein the chemotherapeutic agent is gemcitabine and is applied intravenously at a dose of 1000 mg/m.sup.2 over 30 minutes on Days 1 and 8 of each 21-day cycle.

17. The method of claim 10 wherein the oncolytic adenovirus and the chemotherapeutic agent are administered systemically, regionally, or locally; by intra-arterial, intratumoral, intravenous (IV), parenteral, intra-pleural cavity, or local administration, as intra-tumoral.

Details for Patent 9,056,133

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2039-02-26
Servier Pharmaceuticals Llc ONCASPAR pegaspargase Injection 103411 02/01/1994 ⤷  Try a Trial 2039-02-26
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2039-02-26
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2039-02-26
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.